**Supplemental Information**

Molecular Cell, Volume 43

**Complex Inhibitory Effects of Nitric Oxide on Autophagy**
Sovan Sarkar, Viktor I. Korolchuk, Maurizio Renna, Sara Imarisio, Angeleen Fleming, Andrea Williams, Moises Garcia-Arencibia, Claudia Rose, Shouqing Luo, Benjamin R. Underwood, Guido Kroemer, Cahir J. O’Kane, and David C. Rubinsztein

**FIGURE S1: Relates to Figure 1**

(A) Immunoblot analysis with anti-LC3 antibody shows that DEA NONOate and DETA NONOate reduced LC3-II levels in HeLa cells in a dose-dependent manner.

(B) Immunoblot analysis with anti-LC3 and anti-Atg5 antibodies show the absence of LC3-II and Atg5-Atg12 conjugate in Atg5−/− MEFs compared to Atg5+/+ MEFs. Note that the lanes appearing as separate gel strips in the top panels were derived from non-adjacent lanes from the same exposure of immunoblot from a single gel where all the samples were loaded; the intervening lanes were excised to simplify presentation.

(C) Immunoblot analysis with anti-LC3 antibody shows that HeLa cells treated with 8-pCPT-cGMP had no significant changes in LC3-II levels or on autophagosome synthesis compared to the untreated cells, cultured in the absence (p=0.4427) or presence (p=0.1055) of bafilomycin A₁, suggesting that cGMP has no effects on autophagy.

(D) Analysis of autophagic flux by an automated Cellomics microscope shows that mRFP-GFP-LC3 HeLa cells treated with 8-pCPT-cGMP had no significant change in the number of autolysosomes compared to the untreated cells (p=0.6716).

(E) Assessment of EGFP-HDQ74-transfected HeLa cells with a fluorescence microscope shows that 8-pCPT-cGMP had no significant change in the proportion cells with EGFP-HDQ74 aggregates compared to the untreated cells (p=0.442), suggesting that 8-pCPT-cGMP has no effect on the clearance of autophagy substrate.

(F) Immunoblot analysis with anti-LC3 antibody shows that the effect of DETAl NONOate in reducing autophagosome synthesis in bafilomycin A₁-treated HeLa cells (p=0.0013, without 8-pCPT-cGMP; p=0.0011, with 8-pCPT-cGMP) was not perturbed by the addition of 8-pCPT-cGMP, which itself had no effect on autophagosome synthesis (p=0.9952). As there was no significant change in LC3-II levels between bafilomycin A₁-treated cells cultured in the presence of both the compounds or DETAl NONOate alone (p=0.8911), this suggests that inhibition of autophagic flux by nitric oxide is independent of the cGMP pathway.

Graphical data are represented as mean ±/– SEM. **, p<0.01; NS, Non-significant.

Figure S1. Inhibition of Autophagy by NO Is Independent of the cGMP Pathway

(A) Immunoblot analysis with anti-LC3 antibody shows that DEA NONOate and DETA NONOate reduced LC3-II levels in HeLa cells in a dose-dependent manner.

(B) Immunoblot analysis with anti-LC3 and anti-Atg5 antibodies show the absence of LC3-II and Atg5-Atg12 conjugate in Atg5−/− MEFs compared to Atg5+/+ MEFs. Note that the lanes appearing as separate gel strips in the top panels were derived from non-adjacent lanes from the same exposure of immunoblot from a single gel where all the samples were loaded; the intervening lanes were excised to simplify presentation.

(C) Immunoblot analysis with anti-LC3 antibody shows that HeLa cells treated with 8-pCPT-cGMP had no significant changes in LC3-II levels or on autophagosome synthesis compared to the untreated cells, cultured in the absence (p=0.4427) or presence (p=0.1055) of bafilomycin A₁, suggesting that cGMP has no effects on autophagy.

(D) Analysis of autophagic flux by an automated Cellomics microscope shows that mRFP-GFP-LC3 HeLa cells treated with 8-pCPT-cGMP had no significant change in the number of autolysosomes compared to the untreated cells (p=0.6716).

(E) Assessment of EGFP-HDQ74-transfected HeLa cells with a fluorescence microscope shows that 8-pCPT-cGMP had no significant change in the proportion cells with EGFP-HDQ74 aggregates compared to the untreated cells (p=0.442), suggesting that 8-pCPT-cGMP has no effect on the clearance of autophagy substrate.

(F) Immunoblot analysis with anti-LC3 antibody shows that the effect of DETAl NONOate in reducing autophagosome synthesis in bafilomycin A₁-treated HeLa cells (p=0.0013, without 8-pCPT-cGMP; p=0.0011, with 8-pCPT-cGMP) was not perturbed by the addition of 8-pCPT-cGMP, which itself had no effect on autophagosome synthesis (p=0.9952). As there was no significant change in LC3-II levels between bafilomycin A₁-treated cells cultured in the presence of both the compounds or DETAl NONOate alone (p=0.8911), this suggests that inhibition of autophagic flux by nitric oxide is independent of the cGMP pathway.

Graphical data are represented as mean ±/– SEM. **, p<0.01; NS, Non-significant.
**Figure S2.** NO S-Nitrosylates JNK1, Reduces Bcl-2 Phosphorylation, and Also Increases Bcl-2-Beclin 1 Interaction Independently of Bcl-2 S-Nitrosylation

(A) Flag-JNK1 or pcDNA3.1 (empty vector)-transfected HeLa cells were subjected to biotin derivatization as described in Supplemental Experimental Procedures. Biotinylation of Flag-JNK1 was detected after precipitation with streptavidin agarose and immunoblotting using anti-Flag antibody. Fractions of samples used for precipitation with streptavidin agarose were also run on the immunoblot as inputs. Nitrosylation of Flag-JNK1 was increased in cells treated with DETA NONOate.

(B) Immunoblot analysis with anti-phospho-Bcl-2 (Ser70) antibody shows that DETA NONOate significantly reduced the phosphorylation of Bcl-2 in human cortical neurons (p<0.0001).

(C) Immunoprecipitation with anti-Flag M2 affinity agarose gel and immunoblotting with anti-Bcl-2 antibody shows that DEA NONOate and DETA NONOate increased the interaction of Flag-Beclin 1 with wild-type (WT) Bcl-2 in HeLa cells transfected with WT Bcl-2 along with either empty Flag or Flag-Beclin 1. Note that the lanes appearing as separate gel strips were derived from non-adjacent lanes from the same exposure of immunoblot from a single gel where all the samples were loaded; the intervening lanes were excised to simplify presentation.

(D) Immunoprecipitation with anti-Flag M2 affinity agarose gel and immunoblotting with anti-Bcl-2 antibody shows that DEA NONOate and DETA NONOate increased the interaction of Flag-Beclin 1 with C229A Bcl-2 in HeLa cells transfected with C229A Bcl-2 along with either empty Flag or Flag-Beclin 1, suggesting that the increase in Bcl-2–Beclin 1 association by nitric oxide is independent of Bcl-2 C229A S-nitrosylation. Note that the lanes appearing as separate gel strips were derived from non-adjacent lanes from the same exposure of immunoblot from a single gel where all the samples were loaded; the intervening lanes were excised to simplify presentation.

Graphical data is represented as mean +/− SEM. ***, p<0.001.
Figure S3. NO Activates mTOR under Basal and Starvation Conditions

(A) Immunoblot analysis with anti-JNK1 antibody in WT Jnk1, Jnk1–/– and Jnk2–/– MEFs confirms the absence of JNK1 in Jnk1–/– MEFs.

(B) Immunoblot analysis with anti-phospho-S6 (Ser235/236) antibody shows that DETA NONOate significantly elevated the phosphorylation of S6 in HeLa cells starved with Hank’s Buffered Salt Solution (HBSS) ($p<0.0001$), suggesting that NO activates mTORC1 under starvation condition. Starved cells had significantly lower phospho-S6 levels compared to the cells cultured in full medium (FM) ($p<0.0001$).

(C) Immunoblot analysis with anti-phospho-S6 (Ser235/236) antibody shows that DETA NONOate significantly increased the phosphorylation of S6 in primary mouse ($p<0.0001$) and human cortical neurons ($p<0.0001$), suggesting that NO activates mTORC1 in neurons.

(D) Confocal microscope images of immunofluorescence with anti-mTOR and anti-LAMP1 antibodies in HeLa cells show that DETA NONOate did not alter the distribution of mTOR and lysosomes. Scale bar, 20 µm.

Graphical data are represented as mean +/- SEM. ***, $p<0.001$; **, $p<0.01$; *, $p<0.05$; NS, Non-significant.
Figure S4. NO S-Nitrosylates IKKβ and Reduces AMPK Phosphorylation, and the mTORC1 and JNK1–Bcl-2 Pathways Are Independent of Each Other

(A) Immunoblot analyses with anti-TSC2, anti-phospho-S6K (Thr 389) and anti-phospho-S6 (Ser235/236) antibodies confirm the absence of TSC2 and increased mTOR activity in Tsc2+/− MEFs compared to the Tsc2+/+ MEFs.

(B) IKKβ-Flag or pcDNA3.1 (empty vector)-transfected HeLa cells were subjected to biotin derivatization. Biotinylation of IKKβ-Flag was detected after precipitation with streptavidin-agarose and immunoblotting using anti-Flag antibody. Fractions of samples used for precipitation with streptavidin-agarose were also run on the immunoblot as inputs. Nitrosylation of IKKβ-Flag was increased in cells treated with DETA NONOate.

(C) Immunoblot analysis with anti-phospho-AMPKα (Ser176/180) antibody shows that DETA NONOate reduced the phosphorylation of AMPKα in human cortical neurons.

(D) Immunoblot analyses with anti-IKKβ, anti-phospho-S6K (Thr389) and anti-phospho-S6 (Ser235/236) antibodies confirm the absence of IKKβ and increased mTOR activity in IKKβ−/− MEFs compared to the IKKβ+/+ MEFs. Note that the lanes appearing as separate gel strips in the lower panels were derived from non-adjacent lanes from the same exposure of immunoblot from a single gel where all the samples were loaded; the intervening lanes were excised to simplify presentation.

(E) Immunoblot analysis with anti-phospho-Bcl-2 (Ser70) antibody shows that there was no significant change in Bcl-2 phosphorylation in HeLa cells treated with rapamycin compared to the DMSO-treated cells (p=0.9906).

(F) Immunoblot analysis with anti-phospho-Bcl-2 (Ser70) antibody shows that there was no significant change in Bcl-2 phosphorylation in Tsc2+/− MEFs compared to the Tsc2+/+ MEFs (p=0.9497).

(G) Immunoblot analyses with anti-phospho-S6K (Thr389), anti-phospho-S6 (Ser235/236) and anti-JNK1 antibodies in HeLa or COS-7 cells transfected with either pcDNA3.1 (empty vector) or constitutively active (CA) JNK1 show that there was no difference in mTOR activity in both the cell lines expressing constitutively active (CA) JNK1 compared to the empty vector transfected cells. Graphical data are represented as mean +/− SEM. ***, p<0.001; **, p<0.01; NS, Non-significant.
Figure S5. Stable HEK293 Cell Lines Expressing nNOS, iNOS-GFP or eNOS Have Reduced Starvation-Induced Autophagy, which Is Partly Rescued by L-NAME

(A–C) Immunoblot analyses with anti-nNOS (A), anti-iNOS (B) and anti-eNOS (C) antibodies confirm the expression of the respective NOS isoforms in stable HEK293 cell lines expressing nNOS (A), iNOS-GFP (B) or eNOS (C), respectively, and the absence of endogenous NOS isoforms in HEK293 control cells. Low levels of endogenous nNOS (A) and eNOS (C) were detected in MEFs (A) and HeLa cells (C), respectively.

(D) Confocal microscopy images show the expression of iNOS-GFP in stable HEK293 iNOS-GFP cell line. Scale bar, 10 µm.

(E) Confocal microscopy images show detection of nitric oxide (NO) production by DAF-2DA fluorescent dye in stable HEK293 cell lines expressing nNOS or eNOS (grown under CaCl₂ and L-arginine containing media) upon brief stimulation by ionomycin, whereas treatment of these cell lines with L-NAME prevented NO production as observed by reduced DAF-2DA fluorescence. No fluorescence was observed in HEK293 control cells due to the absence of endogenous NOS isoforms. Scale bar, 20 µm.

(F) Immunoblot analysis with anti-LC3 antibody show elevated LC3-II levels in HEK293 cells starved with Hank’s Buffered Salt Solution (HBSS) compared to cells grown in full media (FM), confirming the induction of autophagy in these cells upon starvation.

(G–J) Immunoblot analyses with anti-LC3 antibody show that stable HEK293 cell lines expressing nNOS (G), iNOS-GFP (H) or eNOS (I) cultured under starvation condition with HBSS had significantly lower LC3-II levels compared to the HEK293 control cells (p<0.0051, nNOS; p<0.0001, iNOS-GFP; p<0.0001, eNOS) (J). Stable HEK293 cell lines treated with L-NAME had small but significant increase in LC3-II levels compared to the untreated nNOS (p=0.0002) (G and J), iNOS-GFP (p=0.0085) (H and J) or eNOS (p<0.0001) (I and J) expressing HEK293 cells. Note that immunoblotting analyses detecting endogenous LC3-II showed that L-NAME partly rescued the levels of autophagy in the stable HEK293 cell lines expressing NOS isoforms, whereas transient overexpression of cherry-LC3 under similar starvation condition showed a complete rescue by L-NAME as in Figures 5E and 5F. Graphical data are represented as mean +/- SEM. ***, p<0.001; **, p<0.01.
Figure S6. Inhibition of Autophagosome-Lysosome Fusion Reduces mTOR Activity

Immunoblot analyses with anti-LC3 and anti-phospho-S6 (Ser235/236) antibodies show that inhibition of autophagosome-lysosome fusion in HeLa cells, treated for 16 h with 200 nM bafilomycin A1, 20 mM NH4Cl or 100 µM chloroquine (all autophagy blockers), increases LC3-II levels (by preventing LC3-II degradation) and reduces mTOR activity as assessed by phosphorylation of S6. Such an effect may explain the reduced mTOR activity (Figures 6A–6F) observed in HEK293 NOS stable cell lines that have impaired autophagy (Figures 5A–5H), which may result due to the cells being chronically starved with autophagy inhibition.
FIGURE S7: Relates to Figure 7

A. Levels of LC3-II relative to actin (%)

B. Levels of LC3-II relative to actin (%)

C. Levels of LC3-II relative to actin (%)

D. mCherry-LC3 in HEK293 cells (HBSS)

E. mCherry-LC3 vesicles (%)

F. EGFP-HDQ74 aggregation

G. EGFP-HDQ74 aggregation

H. EGFP-HDQ74 aggregation

I. HA-A53T α-syn relative to actin (%)

J. Number of mutant huntingtin aggregates in HD zebrafish retina

L-NAME Control

HeLa cells (HBSS)

HEK293 cells (HBSS)
Figure S7. L-NAME Induces Autophagy by Inhibiting Endogenous NOS, Independently of the Bcl-2 and mTOR Pathways, and Enhances the Clearance of Mutant Aggregate-prone Proteins

(A) Immunoblot analysis with anti-LC3 antibody shows that L-NAME significantly increased autophagosome synthesis in bafilomycin A1-treated rat primary cortical neurons (p=0.0027) and HeLa cells (p=0.0128), compared to bafilomycin A1 treatment alone.

(B) Immunoblot analysis with anti-LC3 antibody shows that L-NAME-treated HeLa cells starved with Hank's Buffered Salt Solution (HBSS) significantly increased LC3-II levels in the presence of bafilomycin A1, compared to bafilomycin A1-treated cells alone (p=0.0119), suggesting that L-NAME stimulates autophagy under starvation condition. L-NAME stimulated autophagy under starvation condition also in HEK293 cell lines stably expressing nNOS, iNOS or eNOS (Figures 5E, 5F and S5G–S5J).

(C) Immunoblot analysis with anti-LC3 antibody shows that HEK293 cells (which do not have any endogenous NOS) treated with L-NAME had no significant effects on LC3-II levels and autophagosome synthesis in the absence (p=0.1638) or presence (p=0.1906) of bafilomycin A1, compared to the untreated cells, suggesting that L-NAME induced autophagy by inhibiting endogenous NOS (as seen in L-NAME-treated NOS-overexpressing HEK293 stable cell lines in Figures 5A–5D).

(D and E) Confocal microscopy images (D) and assessment of mCherry-LC3 vesicles with a fluorescence microscope (E) show that mCherry-LC3–transfected HEK293 cells (which do not have any endogenous NOS) starved with HBSS and treated with L-NAME had no significant difference in mCherry-LC3 vesicles compared to untreated mCherry-LC3 transfected cells (p=0.437), suggesting that the effect of L-NAME in stimulating autophagy under starvation condition is mediated by inhibiting endogenous NOS (as seen in NOS-overexpressing HEK293 cell lines in Figures 5E and 5F). Scale bar, 10 µm (D).

(F) Immunoblot analyses with anti-LC3, anti-phospho-S6K (Thr389), anti-phospho-S6 (Ser235/236), anti-phospho-Bcl-2 (Ser70), anti-beclin 1 and anti-cathepsin D antibodies show that HeLa cells treated with L-NAME had increased LC3-II levels (p=0.0015), but had no significant effects on S6K phosphorylation (p=0.6844), S6 phosphorylation (p=0.911), Bcl-2 phosphorylation (p=0.9189), beclin 1 levels (p=0.7713) and cathepsin D levels (p=0.7046) compared to the untreated cells, suggesting that induction of autophagy by inhibition of endogenous NOS is independent of the Bcl2 and mTORC1 pathways.

(G) Assessment of EGFP-HDQ74–transfected SK-N-SH cells with a fluorescence microscope shows that siRNA-mediated nNOS knockdown significantly reduced the proportion cells with EGFP-HDQ74 aggregates compared to the scrambled (control) siRNA-transfected cells (p<0.01). Immunoblot analysis with anti-nNOS antibody confirms a reduction in endogenous nNOS levels with nNOS siRNA.

(H) Immunoblot analysis with anti-EGFP antibody shows that stable inducible PC12 cell line expressing EGFP-HDQ74, induced with doxycycline and followed by treatment with L-NAME in the switch-off period, had significantly lower levels of soluble EGFP-HDQ74 compared to the untreated (control) cells (p<0.0001), suggesting that L-NAME enhanced the clearance of this autophagy substrate.

(I) Immunoblot analysis with anti-HA antibody shows that stable inducible PC12 cell line expressing HA-A53T α-synuclein, induced with doxycycline and followed by treatment with rapamycin (p=0.0011) or L-NAME (p=0.0131) in the switch-off period, had significantly lower levels of soluble HA-A53T α-synuclein compared to the untreated (control) cells, suggesting that both the autophagy inducers enhanced the clearance of this autophagy substrate.

(J) Transgenic Huntington’s disease (HD) zebrafish expressing mutant huntingtin in the retina were treated with autophagy inducers like rapamycin and L-NAME, or with autophagy inhibitors like wortmannin (inhibitor of autophagosome formation) and NH4Cl (blocker of autophagosome-lysosome fusion). Treatment with rapamycin or L-NAME reduced the number of mutant huntingtin aggregates in the retina of transgenic HD zebrafish, whereas treatment with wortmannin or NH4Cl increased the number of aggregates (p<0.01 for all treatment conditions). Note that data in Figures 7H, 7I and S7J are from independent experiments.

Graphical data are represented as mean ± SEM, except for Figure S7G, which is expressed as odds ratio with 95% confidence interval. ***, p<0.001; **, p<0.01; *, p<0.05; NS, Non-significant.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Plasmids
EGFP-HDQ74, mCherry-LC3 (mCherry-hLC3B), Flag-Beclin 1, hVps34, WT Bcl-2 and empty Flag constructs were described previously (Jahreiss et al., 2008; Luo and Rubinsztain, 2010; Narain et al., 1999; Sarkar et al., 2007b; Williams et al., 2008). Constructs received as kind gifts were EGFP-LC3 and mRFP-GFP-LC3 from T. Yoshimori (Kabeya et al., 2000; Kimura et al., 2007), WT Myc-Bcl-2 and AAA Myc-Bcl-2 from B. Levine (Wei et al., 2008), Flag-JNK1 and Flag-MKK7B2Jnk1a1 from A. R. Tee (Addgene plasmids 13798 and 19726) (Derijard et al., 1994; Lei et al., 2002), IKKβ-Flag from W. Greene (Addgene plasmid 23298) (Kolodziejska et al., 2005; Pandit et al., 2009) were grown in the HEK293 cell media supplemented with 600 µg.mL–1 G418. HEK293 cells stably expressing eNOS (HEK293 eNOS) (Liu et al., 1996) were grown in the HEK293 cell media supplemented with 100 µg.mL–1 G418. Stable inducible MEFs (kind gifts from R. J. Davis) (Wei et al., 2008), mCherry (L6785) (all from Sigma-Aldrich), 100 µM L-NAME (Cat. No. A9434), 10 µM lactacystin (L6785) (all from Sigma-Aldrich), 100 µM L-NAME (Cat. No. 483125, Calbiochem), 1 mM 8-pCPT-cGMP (Cat. No. C009, Biolog) and 10 ng.mL–1 TNFa (Cat. No. 315-01A, PeproTech). Cells were treated with NO donors (DEA NONOate, DETA NONOate, SIN-1), L-NAME, 8-pCPT-cGMP and rapamycin for 24 h, unless otherwise indicated. During the treatment with NO modulators, cells were replenished with fresh compounds thrice during the 24 h treatment period.

Compounds used for the treatment in Huntington’s disease (HD) zebrafish model were 30 µM ramapycin (Cat. No. R-5000, LC Laboratories), 1 mM L-NAME (Cat. No. 483125, Calbiochem), 100 nM wortmannin (Cat. No. 681676, Calbiochem) or 10 mM ammonium chloride (NH4Cl) (Cat. No. A9434, Sigma-Aldrich). Compound used for the treatment in HD Drosophila model was 1 mM L-NAME (Cat. No. N5751, Sigma-Aldrich).

Mammalian cell culture and transfection
HeLa cells, HEK293 cells, SK-N-SH cells, Atg5+/− and Atg5−/− MEFs (kind gifts from N. Mizushima) (Kuma et al., 2004), WT Bcl-2 and AAA Bcl-2 MEFs (kind gifts from the laboratory of the late S. J. Korsmeyer) (Wei et al., 2008), WT Jnk, Jnk1−/− and Jnk2−/− MEFs (kind gifts from J. J. Davis) (Tournier et al., 2000), Tsc2+/− and Tsc2−/− MEFs (kind gifts from D. J. Kwiatkowski and A. R. Tee) (Zhang et al., 2003), lkkβ+/− and lkkβ−/− MEFs (kind gifts from M. Karin) (Hacker and Karin, 2006) were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U.mL−1 penicillin/streptomycin and 2 mM L-glutamine (all from Sigma-Aldrich) in 37°C, 5% CO2 humidified incubator. HeLa cells stably expressing mRFP-GFP-LC3 reporter (HeLa mRFP-GFP-LC3 cells) (Sarkar et al., 2009a) were grown in the HeLa cell media supplemented with 600 µg.mL−1 G418 (Invitrogen). HEK293 cells stably expressing nNOS (HEK293 nNOS; kind gift from S. H. Snyder) (Kornberg et al., 2010) were grown in the HEK293 cell media supplemented with 8 µg.mL−1 tyllosin (Sigma-Aldrich). HEK293 cells stably expressing iNOS-GFP (HEK293 iNOS-GFP; kind gift from N. Mizushima) (Kuma et al., 2004) were grown in HEK293 cell media supplemented with 600 µg.mL−1 G418. HEK293 cells stably expressing eNOS (HEK293 eNOS; kind gift from W. C. Sessa) (Liu et al., 1996) were grown in the HEK293 cell media supplemented with 100 µg.mL−1 G418. Stable inducible PC12 stable cell line expressing EGFP-HDQ74 (PC12 EGFP-HDQ74 cells) (Wytenbach et al., 2001) or HA-A53T α-synuclein (PC12 HA-A53T α-synuclein cells) (Webb et al., 2003) were maintained at 75 µg.mL−1 hygromycin B (Calbiochem) in DMEM with 10% horse serum, 5% FBS, 100 U.mL−1 penicillin/streptomycin, 2 mM L-glutamine and 100 µg.mL−1 G418 at 37°C, 10% CO2.

Cells were transfected with DNA constructs for 4 h using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. The amount of DNA used during transfection in various experiments was as follows: 1.5 µg for EGFP-HDQ74 and Flag-CA JNK1; 0.2 µg for mCherry-LC3; 0.5 µg for EGFP-LC3, except for Figure 4E where pcDNA3.1 and AAA Myc-Bcl-2 were used at 1.5 µg along with 0.5 µg of EGFP-LC3 (3:1 ratio); 1 µg of each of the constructs in the immunoprecipitation experiments (1:1 ratio), except in Figure 2G where pcDNA3.1 and AAA Myc-Bcl-2 were used at 1.5 µg along with 0.75 µg of hVps34, empty Flag or Flag-Beclin 1 (2:1:1 ratio) as indicated.

Culture of rat, mouse and human cortical neurons
Primary cortical neurons were isolated from E16.5 Sprague Dawley rat pups (Charles River). Briefly, pup brains were harvested and placed in ice-cold DMEM where the meninges were removed and the cerebral cortices were dissected and incubated in DMEM. After mechanical dissociation using sterile micropipette tips, dissociated neurons were resuspended in DMEM and centrifuged. Cell count and viability assay was performed using the trypan blue exclusion test. Viable cells were seeded on poly-D-lysine and laminin-coated 6-multiwell plates (7.5 x 105 cells per well). Cells were cultured in DMEM supplemented with 2 mM glutamine, 2% B27 supplement and 1% Penicillin-Streptomycin-Fungizone (PSF; Invitrogen) at 37°C in a humidified incubator with 5% CO2 and 95% O2. One-half of the plating medium was changed every third day until treatment. After 7 days of culturing in vitro, the differentiated cortical neurons were used for experiments.
Mouse primary cortical neurons: Mouse primary cortical neuronal cultures were prepared as described previously (Crossthwaite et al., 2002). Briefly, cortices were dissected from 15- to 16-day-old C57BL/6 mouse embryos and mechanically dissociated in PBS (Ca²⁺- and Mg²⁺-free) supplemented with glucose (33 mM). Neurons were plated into multi-well plates coated with 20 μg.mL⁻¹ poly-D-lysine and were maintained in DMEM, supplemented with B-27 (Gibco), 2 mM glutamine, 100 μg.mL⁻¹ streptomycin and 60 μg.mL⁻¹ penicillin, at 37°C and 5% CO₂. Cultures were used after 6–7 days in vitro when the majority of cells were neuronal and there were no detectable glial elements.

Human cortical neurons: ReNcell CX cells, an immortalized human neuronal progenitor cell line with the ability to readily differentiate into cortical neurons, were cultured according to the manufacturer’s instructions (Chemicon, Millpore, MA, USA). Cells were grown in ReNcell NSC maintenance medium supplemented with 20 ng.mL⁻¹ bFGF and 20 ng.mL⁻¹ EGF. Cells were seeded on laminin coated plates and differentiation was initiated with media containing no growth factors for 1 week prior to starting the experiment.

Immunoblot analysis
Cell pellets were lysed on ice in Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 2% sodium dodecyl sulphate, 5% β-mercaptoethanol, 10% glycerol, and 0.01% bromophenol blue) for 30 min in presence of Complete protease inhibitor cocktail (Roche Diagnostics), boiled for 5-7 min at 100°C and subjected to western blot analysis, as previously described (Sarkar et al., 2009b). Primary antibodies include anti-LC3 (1:5,000 dilution; Cat. No. NB100-2220, Novus Biologicals), anti-phospho-Bcl-2 (Ser70) (Cat. No. 2827), anti-phospho-JNK (Thr183/Tyr185) (Cat. No. 9251), anti-p70S6 kinase (Cat. No. 9202), anti-phospho-p70S6 kinase (Thr389) (Cat. No. 9206), anti-S6 ribosomal protein (Cat. No. 2217), anti-phospho-S6 ribosomal protein (Ser235/236) (Cat. No. 2211), anti-TSC2 (Cat. No. 3990), anti-IKKα (Cat. No. 2682), anti-phospho-IKKα/β (Ser176/180) (Cat. No. 2687), anti-AMPKα (Cat. No. 2532), anti-phospho-AMPKα (Ser176/180) (Cat. No. 2531), anti-Beclin 1 (Cat. No. 3738), anti-Cathepsin D (Cat. No. 2284), anti-nNOS (Cat. No. 4231), anti-iNOS (Cat. No. 2977), anti-eNOS (Cat. No. 9586) (all 1:1,000 dilutions from Cell Signaling Technology), anti-Bcl-2 (1:2,000 dilution; Cat. No. sc-492), anti-JNK1 (1:250 dilution; Cat. No. sc-1648) (Santa Cruz Biotechnology), anti-Vps34 (1:500 dilution; Cat. No. 4231), anti-Myo (1:3,000 dilution; Cat. No. 11667203001, Roche Diagnostics), anti-Flag (1:2,000 dilution; Cat. No. F7425 or F3165), anti-HA (1:1,000 dilution; Cat. No. MMS-101R, Covance), rabbit anti-actin (1:4,000; Cat. No. A2066) and anti-tubulin (1:4,000 dilution; Cat. No. T6199). Blots were probed with anti-mouse or anti-rabbit IgG-HRP secondary antibody (1:4,000 dilutions) and visualised using ECL detection kit (GE Healthcare).

Analysis of autophagic flux in mRFP-GFP-LC3 HeLa cells with an automated Cellomics microscope
Assessment of autophagic flux involves the complete flow of the autophagosomes from their formation to fusion with the lysosomes. Counting of autolysosomes in stable HeLa cell line expressing mRFP-GFP-LC3 reporter was performed on a Thermo Scientific Cellomics ArrayScan HCS reader (20x objective) using the Spot detector V3 Cellomics Bioapplication, as previously described (Sarkar et al., 2009a). In mRFP-GFP-LC3 HeLa cells, autophagosomes have both mRFP and GFP signals, whereas the autolysosomes emit only mRFP signal due to quenching of the GFP in the acidic lysosomal environment (Kimura et al., 2007). For identification of cells, nuclei were stained with DAPI and detected on the primary channel by a Hoechst-associated filter dependent upon size, shape, and intensity thresholding. GFP-LC3 and mRFP-LC3 vesicles were identified on separate secondary channels using FITC- and Texas Red-associated filters, respectively, dependent upon size, shape, and intensity thresholding. The mean number of vesicles per cell (object) was calculated by the ArrayScan software as the total number of vesicles per field divided by the total number of objects per field. The number of autolysosomes was analyzed by subtracting GFP dots (spot count per object by FITC-associated filter) from mRFP dots (spot count per object by Texas Red-associated filter). Cells were fixed with 4% formaldehyde and mounted on Citifluor containing DAPI prior to Cellomics analysis. 1,000 cells were counted per coverslip, and the analysis was done on triplicate samples at least twice.

Analysis of autophagosome synthesis by LC3-II levels in the presence of bafilomycin A₁
As the steady state levels of LC3-II are affected both by synthesis and degradation, effects on autophagy are best assessed by clamping LC3-II/autophagosome degradation with bafilomycin A₁. Bafilomycin A₁ inhibits the vacuolar H⁺-
ATPase (V-ATPase) and prevents acidification of autophagosomes and lysosomes, thereby inhibiting LC3-II degradation and resulting in increased LC3-II levels (Fass et al., 2006; Klionsky et al., 2008b; Yamamoto et al., 1998). This is an established method for monitoring autophagosome synthesis (Klionsky et al., 2008a; Mizushima et al., 2010; Rubinsztein et al., 2009; Sarkar et al., 2007b; Sarkar et al., 2009b). An autophagy enhancer will further increase LC3-II levels in the presence of bafilomycin A1, compared to bafilomycin A1 alone, due to an increase in the synthesis of autophagosomes. In contrast, an autophagy inhibitor that prevents autophagosome formation will decrease LC3-II levels in the presence of bafilomycin A1, compared to bafilomycin A1 alone. Autophagosome synthesis was analysed by measuring the levels of LC3-II (immunoblotting with anti-LC3 antibody) in the presence of a saturating concentration (400 nM) of bafilomycin A1, treated for the last 4 h prior to harvesting the cells for immunoblot analysis, as previously described (Rubinsztein et al., 2009; Sarkar et al., 2007a; Sarkar et al., 2007b; Sarkar et al., 2009b).

**Immunofluorescence analysis**

Cells were washed with phosphate-buffered saline (PBS), fixed with 4% formaldehyde for 20 min at room temperature, then washed twice in PBS, followed by permeabilization with 0.5% Triton in PBS for 10 min, and washed once more with PBS. Cells were then blocked in blocking buffer (5% FBS in PBS, or 2% BSA, 2% normal goat serum, 0.05% tween-20 in PBS) for 30 min at room temperature. Cells were incubated overnight at 4°C with primary antibodies, which include anti-Atg16 (1:100 dilution; Cat. No. PM040, MBL), anti-phospho-S6 ribosomal protein (Ser235/236) (1:200 dilution; Cat. No. 2211, Cell Signaling Technology), anti-LAMP1 (1:1500 dilution; Cat. No. H4A3, Developmental Studies Hybridoma Bank), anti-mTOR (1:100 dilution; Cat. No. 2972, Cell Signaling Technology), anti-phospho-mTOR (Ser2448) (1:100 dilution; Cat. No. 2971, Cell Signaling Technology). After washing three times in PBS, 10 min each, cells were incubated for 1 h at room temperature with secondary antibodies, which include Alexa Fluor 488 Green or Alexa Fluor 594 Red-conjugated antibodies (1:1000 dilutions; all raised in goat; Invitrogen). Cells were again washed three times in PBS, 10 min each. Cover slips were air-dried and then mounted on in Citifluor (Citifluor Ltd.) containing 3 µg.mL⁻¹ 4',6-diamidino-2-phenylindole (DAPI; Invitrogen). Images were acquired on a LSM510 META confocal microscope (Carl Zeiss Inc.), with 63x 1.4NA plan-apochromat oil immersion lens at room temperature, using Zeiss LSM510 v3.2 software. For detection of EGFP-LC3 vesicles or mRFP-GFP-LC3 vesicles, standard fluorescence method was used after fixing the cells with 4% formaldehyde and mounted on Citifluor containing DAPI, as described above.

**Immunoprecipitation**

Cells were treated with NO donors in the last 24 h of the 48 h post-transfection period. Immunoprecipitation (IP) was performed using Buffer A (20 mM Tris-HCl pH 7.2, 2 mM MgCl₂, 150 mM NaCl, 0.5% NP-40 and Complete protease inhibitor cocktail). Cells were lysed in Buffer A for 30 min on ice, followed by centrifugation at 13,000 × g for 15 min. A small fraction of the cell lysates were aliquoted and stored (inputs), and the rest (500 µg to 1 mg protein) were incubated overnight at 4°C with anti-Flag M2 affinity agarose gel (Cat. No. A2220, Sigma) or anti-JNK1 agarose-conjugated beads (Cat. No. sc-1648-AC, Santa Cruz Biotechnology), added to a final concentration of 5 µg.mL⁻¹.
Following 3 washings in Buffer A, IP products were directly boiled in Laemmli buffer and subjected to immunoblot analysis, together with the inputs.

**Starvation of mammalian cells for autophagy induction**

Cells were starved in Hanks’ Balanced Salt Solution (HBSS) (Cat. No. H9394, Sigma) to induce autophagy. HeLa cells and HeLa mRFP-GFP-LC3 cells were cultured in HBSS for 6 h to stimulate starvation-induced autophagy. HEK293 cells, HEK293 nNOS cells, HEK293 iNOS-GFP cells and HEK293 eNOS cells were cultured in HBSS for 2 h for stimulating starvation-induced autophagy.

**Analysis of Atg16-positive structures**

HeLa cells, HEK293 cells, HEK293 nNOS cells, HEK293 iNOS-GFP cells and HEK293 eNOS cells were starved in HBSS either for 6 h (HeLa cells) or 2 h (HEK293 cells and stable HEK293 NOS cells) prior to fixation with 4% formaldehyde and then subjected to immunofluorescence analysis with anti-Atg16 antibody, as described above. Cells were assessed with a fluorescence microscope for the percentage of cells containing Atg16-positive structures (phagophores). Images were acquired with a confocal microscope.

**Quantification of mutant huntingtin aggregates**

The percentage of EGFP-positive cells with EGFP-HDQ74 aggregates was assessed with a fluorescence microscope, as previously described (Narain et al., 1999; Sarkar et al. 2005; Sarkar et al., 2007b; Sarkar et al., 2009b). EGFP-HDQ74-transfected cells were treated with compounds in the last 48 h post-transfection period.

**Analysis of clearance of soluble mutant huntingtin**

Stable inducible PC12 cell line expressing EGFP-tagged mutant huntingtin exon 1 with 74 polyglutamine repeats (EGFP-HDQ74) (Wytenbach et al., 2001) was induced with 1 µg.mL\(^{-1}\) doxycycline (Sigma) for 8 h, followed by switching off the transgene expression by removing doxycycline from medium. We have previously shown that the clearance of EGFP-HDQ74 was accelerated upon autophagy induction, leading to lower levels of the transgene-encoded protein, compared to untreated cells after the switch-off period (Ravikumar et al., 2002; Sarkar et al. 2005; Sarkar et al., 2007a; Sarkar et al., 2009b; Williams et al., 2008). Cells were then treated with or without L-NAME for 120 h in the switch-off period, with the compound being replenished every 24 h. Clearance of soluble EGFP-HDQ74 was analysed by immunoblotting with anti-EGFP antibody.

**Analysis of A53T α-synuclein clearance**

Stable inducible PC12 cell line expressing HA-tagged A53T mutant of α-synuclein (HA-A53T α-synuclein) (Webb et al., 2003) was induced with 1 µg.mL\(^{-1}\) doxycycline (Sigma) for 48 h, followed by switching off the transgene expression by removing doxycycline from medium. We have previously shown that the clearance of HA-A53T α-synuclein was accelerated upon autophagy induction, leading to lower levels of the transgene-encoded protein, compared to untreated cells after the switch-off period (Sarkar et al. 2005; Sarkar et al., 2007a; Sarkar et al., 2009b; Webb et al., 2003; Williams et al., 2008). Cells were then treated with or without rapamycin or L-NAME for 24 h in the switch-off period. Clearance of HA-A53T α-synuclein was analysed by immunoblotting with anti-HA antibody.

**Biotin switch assay for S-nitrosylation**

Detection of S-nitrosylated proteins was performed using a kit (Cat. No. 10006518, Cayman Chemical) that employs a modification of the previously described “biotin-switch” method (Jaffrey et al., 2001). Using this method, nitrosyl-groups are replaced with biotin residues. Biotinylated proteins were then precipitated with streptavidin-agarose beads (Cat. No. 20347, Thermo Scientific) and analysed by immunoblotting with anti-Flag antibody (1:2,000 dilution; Cat. No. F3165).

**Detection of nitric oxide production by DAF-2 DA fluorescence**

DAF-2 DA (4,5-Diaminofluorescein diacetate; Cat. No. 85165, Cayman Chemical) is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide. It is the cell-permeable diacetate derivative of DAF-2 that is subsequently hydrolysed in cells by cytosolic esterases, releasing DAF-2, which is relatively non-fluorescent at physiological pH. Generation of nitric oxide in cells converts DAF-2 to the fluorescent triazole derivative, DAF-2T, which can be detected with excitation/emission maxima of 485/515 nm, respectively (Kojima et al., 1998; Kojima et al., 1999). HEK293 cells stably expressing nNOS or eNOS were cultured in HBSS for 1 h followed by addition of 100 µM L-Arginine and 1.3 mM CaCl\(_2\) for an additional 30 min. Cells were then loaded with 10 µM DAF-2 DA for 15 min, followed by stimulation of NOS activity with 3 µM Ionomycin for another 15 min. Cells were fixed with 4% paraformaldehyde and images were acquired with a confocal microscope.

**RNA Interference**

SMARTpool siRNA (pool of four different siRNA duplexes) against human nNOS (Dharmacon) were used for knockdown of nNOS. SMARTpool control siRNA (Dharmacon), which does not target any human or mouse genes,
was used as a control. SK-N-SH cells were transfected with 100 nM SMARTpool siRNAs for 72 h using Oligofectamine (Invitrogen) according to manufacturer’s protocol. Knockdown of nNOS was confirmed by immunoblotting with anti-nNOS antibody.

**Analysis of neurodegeneration in a Drosophila model of Huntington’s disease**

Pseudopupil analysis was performed, as previously described (Franceschini, 1972), by crossing virgin flies of the genotype y w; P(GMR-HD.Q120)2.4 (Q120) (Jackson et al., 1998) with w1118 isogenic males (Ryder et al., 2004). The progeny of the above cross was reared on instant fly food (Philip Harris Ltd.) containing 1 mM L-NAME. Control flies grown in absence of the drug were fed with instant fly food with 0.02% DMSO (Sigma). Flies were treated with drugs both during larval and adult stage. To assess the effect of L-NAME on Q120 flies, t-test analysis was performed on approximately 30 flies, 3 days post-eclosion. Each experiment was based on 4 independent sessions, where 15 ommatidia were scored from approximately 10 individuals of the same genotype. Genetic inhibition of NOS was done by crossing virgin flies of the above genotype to males w; P(GMR-Nos.4.FLAG) (NOS4) (Stasiv et al., 2004). The progeny of Q120 and NOS4 virgins crossed with w1118 isogenic males (Ryder et al., 2004) was used as a control to assess level of neurodegeneration due to Q120 and NOS4 expression. Each experiment was based on 4 independent sessions, where 15 ommatidia were scored from approximately 15 individuals of the same genotype. Fly crosses and experiments were performed at 25°C. All crosses for individual experiments were performed at the same time and under the same conditions.

**Maintenance of zebrafish stocks and collection of embryos**

Zebrafish were reared under standard conditions on a 14 h light:10 h dark cycle (Westerfield, 1995). Embryos were collected from natural spawnings, staged according to established criteria (Kimmel et al., 1995) and reared in embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl₂, 0.33 mM Mg₂SO₄, 5 mM HEPES). Aggregate counting was performed using the heterozygous larvae from the Tg(rho:EGFP-HTT71Q)Q126 zebrafish line (Williams et al., 2008) (hereafter referred to as transgenic HD zebrafish). Compound exposure experiments were performed in the dark at 28.5°C.

**Determination of the maximum tolerated concentration of compounds in larval zebrafish**

Compound exposure experiments were performed on wild-type larvae (TL strain) from 3 days post-fertilization (d.p.f.) to 7 d.p.f. Concentration response assays were performed over half-log intervals, from 1 µM – 100 µM for rapamycin, 1 µM – 1 mM for L-NAME, 1 mM – 300 mM for ammonium chloride (NH₄Cl) and 10 nM – 3 µM for wortmannin, to determine the maximum non-toxic concentration for subsequent aggregate count assays (n = 10 larvae per concentration). The media and compounds were replenished every 24 h.

**Mutant huntingtin aggregate analysis in a transgenic Huntington’s disease zebrafish model**

All zebrafish experiments have been approved by local ethics committee and performed under the appropriate Home Office Licences. Embryos from out-crossed transgenic HD zebrafish were raised in 0.2 mM 1-phenyl-2-thiourea (PTU) medium (Tissue-Tek) and frozen on dry ice for subsequent cryosectioning. Sections were cut at 10 µm thickness using a Leica CM3050 cryostat and mounted in 80% glycerol in PBS. The total number of GFP-positive aggregates was counted over 100 µm of the central retina, either side of the optic nerve using a Zeiss Axiophot2 microscope and mean values were calculated using 6 fish (12 eyes) for each treatment group. Data were compared using ANOVA and Dunnetts post-hoc T-test. Representative images were taken using a Sony CCD digital camera.

**Statistical analyses**

Densitometric analysis on the immunoblots was done by Image J software. The p values for densitometric analysis and Cellomics data were determined by factorial ANOVA test using STATVIEW v4.53 (Abacus Concepts), where the control condition was set to 100% and the data represented as mean ± standard error of mean (SEM). The y-axis values are shown in percentage (%). Experiments were performed in triplicates at least twice. The p values for assessing EGFP-HDQ74 aggregation, EGFP-LC3 or mCherry-LC3 vesicles were determined by unconditional logistical regression analysis, using the general log-linear analysis option of SPSS 9 software (SPSS, Chicago), as previously described (Ravikumar et al., 2008; Sarkar et al., 2007a; Sarkar et al., 2007b; Sarkar et al., 2009b; Williams et al., 2008). **, p < 0.01; *, p < 0.05; NS, Non-significant.
SUPPLEMENTAL NOTES
STATISTICAL ANALYSES DATA (P VALUES) OF FIGURES 1–7

FIGURE 1
(A) Rat primary cortical neurons – DEA NONOate: p=0.0224; DETA NONOate: p=0.042; SIN-1: p=0.0002.
Bafilomycin A1-treated rat primary cortical neurons – DEA NONOate: p=0.0009; DETA NONOate: p=0.0009; SIN-1: p=0.0004.
Bafilomycin A1-treated HeLa cells – DEA NONOate: p=0.0224; DETA NONOate: p=0.042; SIN-1: p=0.0002.

(B) mRFP-GFP LC3 HeLa cells – DEA NONOate: p=0.0011; DETA NONOate: p=0.0007.

(C) mRFP-GFP LC3 HeLa cells – DEA NONOate: p=0.0216; DETA NONOate: p=0.0001; Untreated FM vs Untreated HBSS: p=0.0013.

FIGURE 2
(A) HeLa cells – DEA NONOate: p=0.0018; DETA NONOate: p=0.0019.
(B) HeLa cells – DEA NONOate: p=0.0305; DETA NONOate: p=0.0082.
(c) HeLa cells – pcDNA3.1-transfected cells vs Flag-CA JNK1-transfected cells: p=0.0039; Flag-CA JNK1-transfected cells vs DETA NONOate-treated Flag-CA JNK1-transfected cells: p=0.1951.

(C) HeLa cells – DETA NONOate: p=0.043; DETA NONOate: p=0.0132.

(D) HeLa cells – DETA NONOate: p=0.9079; DETA NONOate: p=0.8109.

(E) HeLa cells – DETA NONOate: p=0.0304; DETA NONOate: p=0.0311.

(G) HeLa cells – AAA Myc-Bcl-2: p=0.0366 (left panel); DETA NONOate + pcDNA3.1: p=0.0006 (right panel); AAA Myc-Bcl-2: p=0.0003 (right panel); DETA NONOate + AAA Myc-Bcl-2: p=0.0002 (right panel); AAA Myc-Bcl-2 vs DETA NONOate + AAA Myc-Bcl-2: p=0.5452 (right panel).

FIGURE 3
(A) WT Bcl-2 MEFs – DETA NONOate: p=0.0077.
AAA Bcl-2 MEFs – DETA NONOate: p=0.024.

(B) WT Bcl-2 MEFs – DETA NONOate: p<0.0001; DETA NONOate: p<0.0001.
AAA Bcl-2 MEFs – DETA NONOate: p<0.0001; DETA NONOate: p<0.0001.

(D) WT Bcl-2 MEFs – DETA NONOate: p<0.0001; DETA NONOate: p<0.0001.
AAA Bcl-2 MEFs – DETA NONOate: p=0.006; DETA NONOate: p=0.027.

(E) WT Jnk MEFs – DETA NONOate: p=0.0048.
Jnk1+/− MEFs – DETA NONOate: p=0.0018.
Jnk2+/− MEFs – DETA NONOate: p=0.0005.

(F) HeLa cells – DETA NONOate: p<0.0001 (P-S6K), p=0.0014 (P-S6); DETA NONOate: p<0.0001 (P-S6K), p=0.0008 (P-S6).

(H) WT Bcl-2 MEFs – DETA NONOate: p=0.0105 (P-S6K), p=0.0001 (P-S6); DETA NONOate: p=0.0058 (P-S6K), p=0.0001 (P-S6).
AAA Bcl-2 MEFs – DETA NONOate: p=0.0122 (P-S6K), p=0.001 (P-S6); DETA NONOate: p=0.0023 (P-S6K), p=0.0001 (P-S6).

FIGURE 4
(A) Tsc2−/− MEFs – DETA NONOate: p=0.0094 (P-S6K), p=0.0243 (P-S6); DETA NONOate p=0.0019 (P-S6K), p=0.0256 (P-S6).
Tsc2−/− MEFs – DETA NONOate: p=0.6355 (P-S6K), p=0.7035 (P-S6); DETA NONOate p=0.8799 (P-S6K), p=0.2561 (P-S6).
(B) MEFs – DETA NONOate: p<0.0001 (P-IKKα/β), p<0.0001 (P-AMPKα); DETA NONOate: p<0.0001 (P-IKKα/β), p<0.0001 (P-AMPKα).

(C) Ikkβ−/− MEFs – DETA NONOate: p<0.0001 (P-S6K), p=0.0053 (P-S6); DETA NONOate p<0.0001 (P-S6K), p=0.0009 (P-S6).
Ikkβ−/− MEFs – DETA NONOate: p=0.22 (P-S6K), p=0.527 (P-S6); DETA NONOate p=0.539 (P-S6K), p=0.1905 (P-S6).

(D) Tsc2−/− MEFs – DETA NONOate: p=0.0009.
Tsc2−/− MEFs – DETA NONOate: p=0.0007.

(E) Tsc2−/− MEFs – pcDNA3.1 + DETA NONOate: p<0.0001; AAA Myc-Bcl-2: p=0.0001; AAA Myc-Bcl-2 + DETA NONOate: p<0.0001; pcDNA3.1 + DETA NONOate vs AAA Myc-Bcl-2 + DETA NONOate: p=0.023.
**FIGURE 5**

(D) LC3 levels in the absence of bafilomycin A1 – HEK293 nNOS cells: \( p = 0.0001 \); HEK293 iNOS-GFP cells: \( p < 0.0001 \).

LC3 levels in the presence of bafilomycin A1 – HEK293 nNOS cells: \( p < 0.0001 \); HEK293 iNOS-GFP cells: \( p < 0.0001 \).

(F) mCherry-LC3 vesicles – HEK293 nNOS cells: \( p < 0.0001 \); HEK293 iNOS-GFP cells: \( p < 0.0001 \); HEK293 eNOS cells: \( p < 0.0001 \);

mCherry-LC3 vesicles in the presence of L-NAME – HEK293 nNOS cells: \( p = 0.002 \); HEK293 iNOS-GFP cells: \( p < 0.0001 \); HEK293 eNOS cells: \( p < 0.0001 \).

(H) Atg16-positive structures – HEK293 nNOS cells: \( p < 0.0001 \); HEK293 iNOS-GFP cells: \( p < 0.0001 \); HEK293 eNOS cells: \( p < 0.0001 \).

**FIGURE 6**

(A) HEK293 nNOS cells (FM) – P-JNK1: \( p = 0.0002 \); P-Bcl-2: \( p = 0.0008 \); P-S6K: \( p < 0.0001 \).

(B) HEK293 iNOS-GFP cells (FM) – P-JNK1: \( p = 0.0002 \); P-Bcl-2: \( p = 0.0033 \); P-S6K: \( p < 0.0001 \).

(C) HEK293 eNOS cells (FM) – P-JNK1: \( p = 0.0003 \); P-Bcl-2: \( p < 0.0001 \); P-S6K: \( p < 0.0001 \).

(D) HEK293 nNOS cells (HBSS) – P-JNK1: \( p = 0.0017 \); P-Bcl-2: \( p = 0.0002 \); P-S6: \( p < 0.0001 \).

(E) HEK293 iNOS-GFP cells (HBSS) – P-JNK1: \( p = 0.0004 \); P-Bcl-2: \( p = 0.0011 \); P-S6: \( p < 0.0001 \).

(F) HEK293 eNOS cells (HBSS) – P-JNK1: \( p = 0.0009 \); P-Bcl-2: \( p < 0.0001 \); P-S6: \( p < 0.0001 \).

**FIGURE 7**

(A) Rat primary cortical neurons – Rapamycin: \( p = 0.0011 \); L-NAME: \( p = 0.0159 \).

HeLa cells – Rapamycin: \( p = 0.0198 \); L-NAME: \( p = 0.0314 \).

(C) mRFP-GFP-LC3 HeLa cells – L-NAME: \( p = 0.0332 \).

(D) Atg5\textsuperscript{+/+} MEFs – L-NAME: \( p < 0.0001 \).

Atg5\textsuperscript{−/−} MEFs – L-NAME: \( p = 0.354 \); Control Atg5\textsuperscript{−/−} MEFs vs Control Atg5\textsuperscript{+/+} MEFs: \( p < 0.0001 \).

(E) Drosophila Q120 + DMSO (Control; Mean ± SEM: 3.2 ± 0.3) vs Drosophila Q120 + L-NAME (Mean ± SEM: 4.4 ± 0.2): \( p < 0.001 \) (paired t-test, based on \( n = 4 \) independent sessions, 15 ommatidia scored from 30 flies per session).

(F) Drosophila Q120 (Control; Mean ± SEM: 3.7 ± 0.2) vs Drosophila Q120 + NOS4 (Mean ± SEM: 4.8 ± 0.5): \( p < 0.05 \) (paired t-test, based on \( n = 4 \) independent sessions, 15 ommatidia scored from 15 flies per session).

(H) HD zebrafish – Rapamycin: \( p < 0.01 \); L-NAME: \( p < 0.01 \).

(I) HD zebrafish – NH\textsubscript{4}Cl: \( p < 0.01 \); L-NAME: \( p < 0.05 \); NH\textsubscript{4}Cl + L-NAME: \( p < 0.01 \).